Research Pipeline
Active and recent human trials targeting aging — from FDA-tracked pharmaceuticals to cutting-edge cell therapies and partial reprogramming.
The landmark TAME trial is the first FDA-endorsed study specifically targeting the biology of aging in non-diabetic older adults. If successful it could enable 'aging' to be listed as a drug indication, opening the floodgates for anti-aging therapeutics.
American Federation for Aging Research (AFAR)
3,000 participants
United States
2027-06
PEARL is a decentralized, placebo-controlled trial comparing four rapamycin dosing regimens in healthy middle-aged adults. It is the first rigorous human trial powered to detect epigenetic age reversal with an mTOR inhibitor.
Ora Biomedical
228 participants
United States
2025-12
The largest randomized trial of rapamycin in any mammal, testing whether mTOR inhibition extends healthspan in middle-aged pet dogs. Dogs serve as an exceptionally translatable model due to shared environment with humans and similar age-related diseases.
University of Washington / Dog Aging Project
580 participants
United States
2026-12
First-in-human trial of senolytic therapy showing that dasatinib plus quercetin reduced senescent cell burden in adipose and skin tissue of patients with diabetic kidney disease. Established proof-of-concept that senolytics can clear senescent cells in humans.
Mayo Clinic
24 participants
United States
2021-08
Pilot RCT demonstrating that intermittent senolytic therapy improved physical function, frailty markers, and quality of life in older adults with underlying physical dysfunction. Provided the clinical rationale for larger Phase 2 and 3 senolytic trials.
Mayo Clinic
20 participants
United States
2021-03
Unity Biotechnology's Phase 2 trial of its Bcl-xL senolytic inhibitor in diabetic macular edema. The trial showed a durable single-injection effect lasting up to 6 months, suggesting senolytics may offer a long-acting alternative to frequent anti-VEGF injections.
Unity Biotechnology
63 participants
United States
2023-09
Landmark placebo-controlled trial showing NMN (250 mg/day for 10 weeks) significantly increased skeletal muscle insulin sensitivity and NAD+ metabolism in postmenopausal women with prediabetes. Published in Science in 2021.
Washington University School of Medicine
25 participants
United States
2021-07
Multi-dose comparison trial testing 300 mg vs 600 mg vs 900 mg NMN daily in adults aged 65+ to determine optimal dosing for NAD+ restoration and physical performance outcomes. Results will directly inform human dosing guidelines.
ProHealthspan / University of Colorado
80 participants
United States
2025-09
Demonstrated that oral NR supplementation dose-dependently raised whole blood NAD+ by 40–60% in healthy middle-aged and older adults without significant side effects, establishing the human pharmacodynamics of NAD+ precursor supplementation.
ChromaDex / University of Colorado
30 participants
United States
2020-08
Double-blind RCT testing whether spermidine-rich plant extract (1.2 mg/day spermidine) slows cognitive decline in older adults at risk for dementia. Building on autophagy-induction preclinical data showing neuroprotective effects.
Charité – Universitätsmedizin Berlin
100 participants
Germany
2022-12
First human trial of Urolithin A demonstrating improved mitochondrial and cellular health biomarkers in older adults. Published in Nature Metabolism, showing significant improvement in muscle endurance at 1 g/day versus placebo.
Amazentis SA
66 participants
Switzerland, United States
2021-03
Pivotal Phase 3 trial of Urolithin A (1 g/day) in older adults, testing whether mitophagy activation can meaningfully improve aerobic capacity and physical function. A positive result would support the first approval for a mitophagy-targeting nutraceutical.
Amazentis SA
240 participants
United States, Switzerland, France
2026-06
First-in-human trial of partial epigenetic reprogramming using AAV-delivered Yamanaka factors (OSK) to reverse age-related optic nerve damage. Pioneered by David Sinclair's lab and now entering the clinic in glaucoma patients.
Rejuvenate Bio / Mass Eye and Ear
15 participants
United States
2026-09
Proof-of-concept trial of GRF6019 — a concentrated albumin-free plasma fraction derived from young donors — in mild-to-moderate Alzheimer's disease. Demonstrated safety and potential stabilization of functional decline over 4 weekly infusions.
Alkahest
18 participants
United States
2018-08
Phase 1 trial of a proprietary young plasma fraction testing safety and early signs of efficacy in frail older adults. Alkahest's proteomics platform identified specific plasma proteins that decline with age and drove formulation of GRF6021.
Alkahest (a Grifols company)
40 participants
United States
2025-03
Extension of the TRIIM trial that showed a combination of growth hormone, DHEA, and metformin reversed epigenetic age by 2.5 years on average. TRIIM-X expands enrollment and duration to confirm and extend these remarkable findings.
Intervene Immune
85 participants
United States
2025-12
Randomized trial of high-dose fisetin (20 mg/kg for 2 consecutive days per month) as a senolytic in adults 70+. Designed to test whether clearing senescent cells with a natural flavonoid can meaningfully reduce frailty and inflammation.
Mayo Clinic
120 participants
United States
2025-09
The most rigorous caloric restriction trial in humans, showing 25% CR reduced cardiometabolic risk factors and slowed a composite aging clock over 2 years in non-obese adults. Landmark results published in Lancet Diabetes & Endocrinology.
National Institute on Aging (NIA)
220 participants
United States
2012-08
Well-powered RCT comparing 8-hour time-restricted eating (TRE) to unrestricted eating in adults with obesity. Results added nuance to TRE: weight loss was modest and primarily lean mass, highlighting the importance of protein intake during the feeding window.
UCSF
116 participants
United States
2023-05
One of the largest exercise longevity trials ever conducted, comparing supervised HIIT to moderate-intensity continuous training in community-dwelling older adults. Will provide definitive data on which exercise modality most robustly extends cardiorespiratory fitness.
Norwegian University of Science and Technology
1,500 participants
Norway
2026-12
Phase 3 trial of RTB101, a selective TORC1 inhibitor, testing whether mTOR inhibition could reduce respiratory infection severity in older nursing home residents during COVID-19. Terminated early due to insufficient efficacy signal in the primary endpoint.
resTORbio
540 participants
United States
2021-09
First-in-human study of recombinant GDF11, a blood-borne factor identified in parabiosis experiments that declines with age and appears to reverse multiple aging phenotypes in mice. This dose-escalation trial will establish human safety and bioavailability.
Elevian
32 participants
United States
2025-06
Pioneering Phase 1 safety study of CRISPR-mediated telomerase delivery in Hutchinson-Gilford Progeria Syndrome patients. While targeting an ultra-rare accelerated aging disease, the trial provides the first clinical safety data for CRISPR-based telomere extension strategies.
Telomere Therapeutics / Children's Hospital Colorado
12 participants
United States
2027-06
First-in-human trial of CAR-T cells engineered to recognize and destroy p16-positive senescent cells, inspired by the landmark Weissman lab mouse studies showing dramatic rejuvenation after senescent cell clearance. Targeting fibrosis as an initial indication.
Agenus / Cold Spring Harbor Laboratory
18 participants
United States
2026-12
Randomized trial of resveratrol (1 g twice daily) in healthy older adults testing cognitive and biomarker outcomes. Results showed hippocampal functional connectivity improvements and memory trends in women, but mixed effects overall.
Georgetown University
60 participants
United States
2019-12
Early phase trial testing intravenous infusion of mesenchymal stem cell-derived exosomes in frail older adults. Exosomes carry regenerative signaling cargo that may mediate the beneficial effects of young blood and stem cell therapies without the cells themselves.
Kimera Labs / University of Miami
30 participants
United States
2025-11
Pilot open-label trial demonstrating that three 3-day courses of dasatinib plus quercetin significantly reduced senescent cell markers, improved 6-minute walk distance by 39 m, and enhanced physical function in patients with idiopathic pulmonary fibrosis.
Mayo Clinic
14 participants
United States
2019-09
Double-blind RCT testing calcium alpha-ketoglutarate (CaAKG, 2 g/day) — a TCA cycle intermediate and DNA methylation substrate — for epigenetic age reversal in adults 55–70. Motivated by mouse data showing 12% lifespan extension with AKG.
Ponce Health Sciences University / AgelessRx
120 participants
United States
2025-08
Combination trial testing whether apigenin (a CD38 inhibitor) plus NMN produces greater NAD+ elevation than NMN alone. CD38 is the primary NAD+-consuming enzyme that increases with age, and its inhibition could dramatically amplify NAD+ precursor efficacy.
AgelessRx
150 participants
United States
2025-12
Large-scale trial motivated by epidemiological data showing regular glucosamine users have ~15% lower all-cause mortality. Tests the hypothesis that glucosamine mimics low-carbohydrate diet signals and activates AMPK, producing longevity benefits independently of its joint-protective effects.
VA Health Care System
1,000 participants
United States
2030-01
One of the most comprehensive longevity intervention trials in Europe, testing the three-way combination of omega-3 fatty acids, vitamin D, and simple home exercise in European adults 70+. Published in JAMA with results across multiple aging outcomes.
University of Zurich
2,157 participants
Switzerland, Austria, Germany, France, Portugal
2018-11
RCT testing the combination of two imidazole dipeptides — carnosine and anserine (abundant in chicken breast) — on telomere biology and aging biomarkers in adults 60+. Driven by epidemiological data linking high imidazole dipeptide intake to slower cognitive aging.
Kyushu University
60 participants
Japan
2025-03
Important trial revealing that metformin may blunt exercise adaptations — particularly mitochondrial biogenesis and muscle mass gains — when combined with structured training. Results challenged the assumption that metformin and exercise are purely additive.
Joslin Diabetes Center
53 participants
United States
2022-06
First systematic safety and pharmacokinetics study of intravenous NAD+ administration in healthy adults, testing whether IV delivery achieves superior NAD+ restoration compared to oral precursors. Includes methylation clock readouts as secondary endpoints.
Jinfiniti Precision Medicine
40 participants
United States
2025-11
Translational trial of recombinant irisin, an exercise-induced myokine that crosses the blood-brain barrier and reverses Alzheimer's pathology in mouse models. The trial tests whether peripheral irisin administration can replicate the cognitive benefits of aerobic exercise in older adults.
Harvard Medical School / Brigham and Women's Hospital
24 participants
United States
2026-09
Head-to-head comparison of berberine plus NMN versus metformin in older adults with prediabetes, testing whether the natural combination matches the metabolic benefits of the pharmaceutical with fewer GI side effects and added NAD+ benefits.
University of Queensland
90 participants
Australia
2026-03
First-in-human trial of recombinant klotho, an aging-suppressor protein that declines dramatically with age and whose overexpression extends lifespan by 30% in mice. The trial will test whether acute klotho restoration is safe and can improve cognitive and kidney aging biomarkers.
Unity Through Knowledge Fund / UCSF
20 participants
United States
2028-06
Notable trial showing that a 60-session hyperbaric oxygen protocol significantly lengthened telomeres (25% increase) and reduced senescent cell burden in healthy older adults. Published in Aging, prompting debate about the mechanisms and reproducibility of these findings.
Tel Aviv University / Shamir Medical Center
35 participants
Israel
2022-06
Building on the 2022 Nature Aging paper showing FMT from young mice reversed aging in old mice, this trial tests whether young-donor FMT can improve frailty and reduce systemic inflammation in older adults. The first human trial targeting microbiome rejuvenation for longevity.
Longevity Biotech / University of Exeter
80 participants
United Kingdom
2026-12
Everspan